July 2018
Volume 59, Issue 9
ARVO Annual Meeting Abstract  |   July 2018
Pathophysiology of chemotherapy induced retinopathy
Author Affiliations & Notes
  • Elon H. Van Dijk
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Footnotes
    Commercial Relationships   Elon Van Dijk, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4408. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elon H. Van Dijk; Pathophysiology of chemotherapy induced retinopathy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4408.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : The exact origin of the serous retinopathy that can develop in patients with metastatic cancer, who are treated with mitogen-activated protein kinase kinase inhibition, is yet unknown. To further optimize treatment for this vulnerable patient group, an overview of several cell layers of importance and other factors that may be involved in this retinopathy will be provided during this talk.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.